Becton, Dickinson and Company (BDX) to Issue Quarterly Dividend of $1.05 on September 30th

Becton, Dickinson and Company (NYSE:BDX) announced a quarterly dividend on Tuesday, July 28th. Stockholders of record on Wednesday, September 9th will be paid a dividend of 1.05 per share by the medical instruments supplier on Wednesday, September 30th. This represents a c) dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Wednesday, September 9th.

Becton, Dickinson and Company has increased its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 53 consecutive years. Becton, Dickinson and Company has a dividend payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Becton, Dickinson and Company to earn $13.48 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 31.2%.

Becton, Dickinson and Company Trading Up 1.3%

Becton, Dickinson and Company stock opened at $168.56 on Thursday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The stock has a market capitalization of $46.44 billion, a PE ratio of 42.67, a price-to-earnings-growth ratio of 11.77 and a beta of 0.21. The firm has a 50 day simple moving average of $151.10 and a 200-day simple moving average of $163.89.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Stifel Nicolaus cut their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Bank of America lowered their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Barclays upped their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Weiss Ratings lowered shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, Piper Sandler lowered their price objective on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and a consensus price target of $180.93.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.